Neogen posts Q4 FY26 core growth, updates on Petrifilm shift and genomics sale timeline
Food safety core growth hit its best pace since fiscal 2023 as Neogen advanced its Petrifilm manufacturing move and the pending Zoetis genomics divestiture.
Neogen Corporation reported fourth quarter and full fiscal year 2026 results on July 30, 2026, covering the period ended May 31, 2026.
On manufacturing, the company said it is on track to manufacture sellable Petrifilm product and begin a planned multi-quarter transition of Petrifilm manufacturing to its Lansing site starting in November 2026, with the first fully validated SKU expected by the end of August 2026.1
Regarding the previously announced divestiture, Neogen said it expects to complete the sale of its global genomics business to Zoetis Inc. before the end of the first half of fiscal year 2027, with total proceeds anticipated at $160 million and net proceeds after taxes and closing costs of approximately $140 million1, funds the company said it plans to use mainly to pay down debt.1 The deal remains under antitrust review: in July, both the Australian Competition and Consumer Commission and the New Zealand Commerce Commission moved their reviews of the genomics divestiture into a second phase, and Neogen said it will keep cooperating with both regulators.1
On animal health matters, Neogen said it is supporting efforts against the New World Screwworm and received expanded federal pesticide-label recommendations allowing use of two of its Prozap products in screwworm response, giving ranchers and livestock producers an added option for fly management.1
Financially, Neogen reported fourth quarter revenue of $225.3 million, described as representing growth of (0.1%) and Core Growth of 4.3%, with full fiscal year 2026 revenue of $870.4 million1. Food Safety core revenue growth reached 5.8% in the quarter, which the company called the highest rate since shortly after it acquired 3M's Food Safety business in fiscal 20231.
For fiscal 2027, Neogen guided to total revenue of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million1, figures that still include an estimated $92 million of revenue and $13 million of adjusted EBITDA tied to the genomics unit, guidance the company said it will update once that sale closes.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.